Biotech

All Articles

Lykos will inquire FDA to reconsider its own choice following rejection of MDMA therapy for trauma

.Adhering to an unsatisfactory presenting for Lykos Therapeutics' MDMA applicant for post-traumatic ...

AN 2 fifty percents roll call, quits stage 3 trial after data disappoint

.AN2 Therapeutics is actually reassessing its service in action to uninspired midphase information, ...

Merck spends $700M for bispecific, spying autoimmune position and opportunity to challenge Amgen in cancer

.Merck &amp Co. is paying $700 thousand ahead of time to challenge Amgen in a blood stream cancer ce...

Gilead spends J&ampJ $320M to exit licensing package for seladelpar

.With Gilead Sciences about to an FDA choice for its own liver health condition medication seladelpa...

' All palms on deck' at Lilly as peers target weight problems market

.CEO David Ricks can easily observe the providers putting together tents at basecamp behind Eli Lill...

Entero laying off personnel, abandoning office and stopping R&ampD

.Bed Liquidators has turned Entero Therapies white as a sheet. The financial institution bought Ente...

Exelixis drops ADC after deciding it's no match for Tivdak

.Exelixis is surrendering on its tissue element (TF)- targeting antibody-drug conjugate after conclu...

Relay dislikes SHP2 prevention after Genentech leaves

.Three weeks after Roche's Genentech device left an SHP2 prevention treaty, Relay Therapy has affirm...

Stoke's Dravet syndrome med discharged of predisposed medical grip

.Stoke Therapeutics' Dravet disorder medicine has been freed from a partial grip, getting rid of the...

Fierce Biotech's Gabrielle Masson provides Intense 15 at NYSE

.Brutal Biotech Associate Publisher Gabrielle Masson provided the 2024 training class of Ferocious 1...